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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) productively infects only humans and chimpanzees but 
not Old World monkeys, such as rhesus and cynomolgus (CM) monkeys. To establish a monkey model of HIV-1/AIDS, 
several HIV-1 derivatives have been constructed. We previously reported that efficient replication of HIV-1 in CM cells 
was achieved after we replaced the loop between α-helices 6 and 7 (L6/7) of the capsid protein (CA) with that of 
SIVmac239 in addition to the loop between α-helices 4 and 5 (L4/5) and vif. This virus (NL-4/5S6/7SvifS) was supposed 
to escape from host restriction factors cyclophilin A, CM TRIM5α, and APOBEC3G. However, the replicative capability of 
NL-4/5S6/7SvifS in human cells was severely impaired.
Results: By long-term cultivation of human CEMss cells infected with NL-4/5S6/7SvifS, we succeeded in rescuing the 
impaired replicative capability of the virus in human cells. Sequence analysis of the CA region of the adapted virus 
revealed a G-to-E substitution at the 116th position of the CA (G116E). Introduction of this substitution into the 
molecular DNA clone of NL-4/5S6/7SvifS indeed improved the virus' replicative capability in human cells. Although the 
G116E substitution occurred during long-term cultivation of human cells infected with NL-4/5S6/7SvifS, the viruses 
with G116E unexpectedly became resistant to CM, but not human TRIM5α-mediated restriction. The 3-D model 
showed that position 116 is located in the 6th helix near L4/5 and L6/7 and is apparently exposed to the protein surface. 
The amino acid substitution at the 116th position caused a change in the structure of the protein surface because of 
the replacement of G (which has no side chain) with E (which has a long negatively charged side chain).
Conclusions: We succeeded in rescuing the impaired replicative capability of NL-4/5S6/7SvifS and report a mutation 
that improved the replicative capability of the virus. Unexpectedly, HIV-1 with this mutation became resistant to CM 
TRIM5α-mediated restriction.
Background
Human immunodeficiency virus type 1 (HIV-1) produc-
tively infects only humans and chimpanzees, but not Old
World monkeys (OWM) such as cynomolgus (CM) and
rhesus (Rh) monkeys [1]. Unlike the replication of simian
immunodeficiency virus isolated from macaques (SIV-
mac), HIV-1 replication is blocked early after viral entry,
before the establishment of a provirus in OWM cells [1-
3]. To establish a monkey model of HIV-1/AIDS, several
viruses that are chimeras of HIV-1 and SIVmac (SHIV)
have been constructed and tested for replicative capabil-
ity in simian cells [4,5]. The host range of HIV-1 was lim-
ited because of some intrinsic restriction factors in
simian cells, such as ApoB mRNA editing catalytic sub-
unit (APOBEC) 3G [6], cyclophilin A (CypA) [7-9], BST-2
(CD317; tetherin) [10,11] and TRIM5α, a member of the
tripartite motif (TRIM) family proteins [12]. Rh and CM
TRIM5α restrict HIV-1, but not SIVmac [13,14]. A lack of
functional TRIM5α expression in pig-tailed monkey
enabled Hatziioannou et al. to construct a SHIV strain
that differs from HIV-1 only in the vif gene and can effi-
ciently replicate in pig-tailed monkeys [15]. Although this
virus was designed to escape from monkey APOBEC3G
mediated restriction, this virus failed to grow in Rh and
CM cells. Kamada et al. attempted to evade the restric-
tions mediated by CypA in OWM cells by replacing the
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loop between α-helices 4 and 5 (L4/5) of the HIV-1 capsid
(CA) with that of SIVmac in addition to vif because CypA
fails to bind to the L4/5 of SIVmac. However, this was not
e n o u g h  t o  e s c a p e  f r o m  T R I M 5 α - m e d i a t e d  r e s t r i c t i o n
[16].
TRIM5α consists of RING, B-box 2, coiled-coil, and
SPRY (B30.2) domains [17]. TRIM5α recognizes the mul-
timerized CA of an incoming virus by its α-isoform spe-
cific SPRY domain [18-20]. Studies on chimeric TRIM5αs
have shown that the determinant of the species-specific
restriction against viral infection resides in the variable
regions of the SPRY domain [21,22]. On the other hand,
we previously identified a single amino acid of the sur-
face-exposed loop between α-helices 6 and 7 (L6/7) of the
HIV-2 CA as a determinant of the susceptibility of HIV-2
to CM TRIM5α[23]. On the basis of this finding, we have
succeeded in improving simian-tropic HIV-1, which was
generated by Kamada et al. [5], by replacing L6/7 of CA
with those of SIVmac239 in addition to L4/5 and vif [24];
the new resultant virus has more efficient replication in
CM cells. The resultant virus, NL-ScaVR6/7S, showed
efficient replicative capability in CM cells; however, the
replicative capability of this virus in human cells was
severely impaired.
In the present report, we describe our efforts to rescue
the impaired replicative capability of NL-ScaVR6/7S after
long-term cultivation in human CEMss cells, and we
report on the amino acid mutation that improved the
replicative capability of this virus.
Materials and methods
Viral adaptation
For viral adaptation in human cells, 100 ng of p24 of NL-
ScaVR6/7S [24], renamed in this report as NL-4/5S6/
7SvifS, was inoculated into 1 × 106 of human T cell line
CEMss cells. The infected culture was gradually
expanded to keep the cell concentration at 1 × 106/mL.
The culture supernatants were collected periodically, and
p24 levels were measured with an ELISA kit (ZeptoMe-
trix, Buffalo, NY). Virus in the culture supernatant at day
42 after infection was designated NL-4/5S6/7SvifSd42,
and inoculated into fresh CEMss cells. Six days after re-
infection, the matrix (MA)-CA region of the integrated
provirus was amplified by PCR from the genomic DNA of
infected cells and cloned into pCR 2.1-TOPO vector
(Invitrogen, Carlsbad, CA) to generate pTopo-MA-
CAadp42. Nucleotide sequences of 6 independent clones
were determined by ABI Prism 3100 Genetic Analyzer
(Applied Biosystems, USA).
DNA constructions
The HIV-1 derivatives were constructed on a backbone of
infectious molecular clone NL4-3 [25]. To introduce a
glycine (G)- to-glutamic acid (E) substitution at the 116th
position of CA (G116E) into NL-4/5S6/7SvifS, the 0.5 kb
SpeI-ApaI fragment, which corresponds to the N-termi-
nus of the CA including the 116th position and L6/7, of
pTopo-MA-CAd42 was transferred into NL-4/5S6/7SvifS
to generate NL-4/5SG116E6/7SvifS. The G116E substitu-
tion was also introduced into NL4-3 and NL-SVR
(renamed NL-vifS in this report) by site-directed muta-
genesis with the PCR-mediated overlap primer extension
method. Resultant constructs were designated NL-G116E
and NL-G116EvifS, respectively (Figure 1). To construct
the wild type and mutant HIV-1 clones expressing green
fluorescence protein (GFP), the 1.3 kb BssHII-ApaI frag-
ment of NL-G116E, NL-4/5S6/7SvifS, or NL-4/
5SG116E6/7SvifS, which corresponds to the MA and CA,
was transferred to NL-Nhe GFP, in which the env gene
was interrupted; and the GFP gene was inserted into the
nef region. Resultant constructs were designated G116E-
GFP, 4/5S6/7S-GFP, and 4/5SG116E6/7S-GFP, respec-
tively. To construct the lentivector expressing GFP under
the control of cytomegalovirus promoter, we replaced the
Eco RI-Apa I fragment corresponding to MA and CA of
the pMDLg/p.RRE packaging vector [24,26,27] with that
of NL-G116E, and designated the resultant construct as
pMDLg/p.RRE-G116E.
Cells and virus propagation
The human kidney adherent 293T cells were cultured in
Dulbecco's modified Eagle medium supplemented with
10% heat-inactivated fetal bovine serum (FBS). The
human T cell lines CEMss and MT4 were maintained in
RPMI 1640 medium supplemented with 10% FBS. Virus
stocks were prepared by transfection of 293T cells with
HIV-1 NL4-3 and its derivatives using the calcium phos-
phate co-precipitation method. Viral titers were mea-
sured with an ELISA kit.
Sendai viruses (SeV) expressing CM TRIM5α, human
TRIM5α, Rh TRIM5α, and CM TRIM5α without the
SPRY domain [CM-SPRY (-)] were described previously
[18,23,28].
A cell line stably expressing CM or humanTRIM5α was
established as described previously [18]. Briefly, a pCEP4
plasmid (Invitrogen) encoding CM or human TRIM5α
fused with HA tag in its C-terminus was transfected into
TK-ts13 hamster cells. Transfected cells were then cul-
tured in the presence of 0.3 mg/ml of hygromycin B
(Gibco) for 14 days to remove untransfected cells. The
expression of TRIM5α was confirmed by Western blot
analysis of cell lysate with anti-HA antibody (HA High
Affinity, Roch).
Viral infections
CEMss or MT4 cells (1 × 105) were infected with 20 ng of
p24 of NL-4/5SvifS, NL-4/5S6/7SvifS, or NL-4/
5SG116E6/7SvifS. The culture supernatants were col-
lected periodically, and p24 levels were measured with an
ELISA kit. To analyze the viral sensitivity to TRIM5α, 1 ×Kuroishi et al. Retrovirology 2010, 7:58
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105 CEMss cells were first infected with SeV expressing
each of the TRIM5αs at a multiplicity of infection of 10
plaque-forming units per cell and incubated at 37°C for 9
hours. Cells were then superinfected with 20 ng of p24 of
HIV-1 NL4-3 or its derivatives. The culture supernatants
were collected periodically, and the levels of p24 were
measured with an ELISA kit.
For the single-round infection assay, CEMss or canine
Cf2Th cells were infected with SeV expressing TRIM5α
as described above, and super-infected with vesicular
stomatitis virus glycoprotein (VSV-G) pseudotyped HIV-
1 clones expressing GFP. In case of TK-ts13 hamster cells
stably expressing CM, human or CM-SPRY(-) TRIM5α,
cells were infected with VSV-G pseudotyped lentivector
expressing GFP under the control of cytomegalovirus
promoter. Two days after infection, the cells were fixed by
formaldehyde, and GFP expressing cells were counted
with a flow-cytometer. The percentage of the GFP-posi-
tive cells in the presence of TRIM5α was divided by the
percentage of GFP-positive cells in the presence of CM-
SPRY (-) to define the percent of infection. The differ-
ences in percent infection between WT-GFP and G116E-
GFP, or 4/5S6/7S-GFP and 4/5SG116E6/7S-GFP were
statistically evaluated by using the unpaired t test.
Particle purification and Western blotting
The culture supernatants of 293T cells transfected with
plasmids encoding HIV-1 NL4-3 derivatives were clari-
fied by low-speed centrifugation. Nine milliliters of the
resultant supernatants were layered onto a 2 mL cushion
of 20% sucrose in phosphate buffered saline (PBS) and
centrifuged at 35,000 rpm for 2 hours in a Beckman
SW41 rotor. After centrifugation, the virion pellets were
resuspended in PBS, and p24 antigen concentrations
were measured by ELISA. Fifty nanograms of p24 of HIV-
1 derivatives were applied to SDS-polyacrylamide gel
electrophoresis, and the virion-associated proteins were
transferred to a PVDF membrane. CA and CypA proteins
were visualized with the anti-p24 antibody (Abcam) and
anti-CypA antibody (Affinity BioReagents, Golden, CO),
respectively.
Modeling
The structure of the N-terminal domain of the HIV-1 CA
protein (PDB number 1GWP) [29] was used as a template
for building the domain model with the G116E substitu-
Figure 1 Schematic representation of HIV-1 derivatives. White and gray bars denote HIV-1 (NL4-3) and SIVmac239 sequences, respectively. "E" 
indicates the amino acid residue at the 116th position of the capsid protein (CA).
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tion. The model was built using Modeller 9v4 [30] and
visualized with PyMOL v1.0r2 (The PyMOL Molecular
Graphics System, http://pymol.sourceforge.net/).
Results
A virus with SIVmac CA L4/5, L6/7, and vif gained efficient 
replicative capability after adaptation in human T cell line
We previously reported that in addition to L4/5 of the CA
and vif, L6/7 of the SIVmac CA is important for the effi-
cient replication of HIV-1 derivatives in CM cells [24].
While introduction of SIVmac L6/7 into an HIV-1 deriva-
tive improved viral growth in CM cells, the replicative
capability in human cells was greatly attenuated. To gain
more insight into the effects of the L6/7 replacement on
viral replication, we attempted to rescue the impaired
replicative capability by long-term cultivation in human
CEMss cells. NL-ScaVR6/7S, a virus with SIVmac L4/5,
L6/7, and vif  renamed NL-4/5S6/7SvifS in the present
study, was inoculated into CEMss cells; and culture
supernatants were periodically assayed for the levels of
p24. Progeny virions were first detectable on day 20 after
infection and reached a peak titer on day 42 (Figure 2A).
The virus in the culture supernatant on day 42 was desig-
nated NL-4/5S6/7SvifSd42 and inoculated into fresh
CEMss cells (Figure 2B). This time, the progeny virus was
detectable on day 3 and reached a peak on day 20, sug-
gesting that the NL-4/5S6/7SvifSd42 gained certain
mutation(s) that overcame the attenuated replicative
capability. Therefore, we amplified by PCR and cloned
the integrated proviral DNA corresponding to the MA
and CA regions in the NL-4/5S6/7SvifSd42-infected
CEMss cells on day 6. Nucleotide sequence analysis of the
resultant clones revealed that 6 out of 6 independent
clones carried a single nucleotide substitution at the
347th position of the CA region, resulting in a G-to-E
substitution at the 116th position of the CA (G116E).
Analysis of 95 HIV-1 strains in the Los Alamos HIV
sequence databases http://www.hiv.lanl.gov/, including
subtypes A to K of group M, revealed that there was no
HIV-1 strain carrying glutamic acid at the 116th position
of the CA, although this position was occupied with vari-
able amino acid residues (35 strains carried glycine; 36,
alanine; 9, threonine; 7, arginine; 6, glutamine; 1 each,
isoleucine or aspartic acid).
A single amino acid substitution in CA rescued impaired 
replicative capability in human cells
To determine whether the single amino acid substitution
at the 116th position of the CA improved the replicative
capability of NL-4/5S6/7SvifS in human cells, we intro-
duced the G116E mutation into NL-4/5S6/7SvifS. Resul-
tant viruses were designated NL-4/5SG116E6/7SvifS and
inoculated into human CEMss or MT4 cells together
with their parental viruses to analyze their replicative
capability (Figure 3). As described previously [24], NL-4/
5S6/7SvifS showed less efficient growth in both CEMss
and MT4 human cell lines than did NL-4/5SvifS. NL-4/
5SG116E6/7SvifS could grow more efficiently in both
human cells than did the parental NL-4/5S6/7SvifS, and
its growth was comparable to that of NL-4/5SvifS (Figure
3). These data suggest that the rescued replicative capa-
bility of NL-4/5S6/7SvifSd42 in human cells (Figure 2)
was the result, at least partly, of the acquisition of the
G116E substitution in the CA.
The amino acid residue at the 116th position of the CA 
affects viral growth in the presence of TRIM5α
We previously reported that NL-4/5S6/7SvifS could grow
in CM cells [24], but failed to directly demonstrate that
this virus could grow in human cells expressing CM
TRIM5α because of its impaired growth capability in
human cells. Because the G-to-E substitution at the116th
Figure 2 Adaptation of HIV-1 derivatives to human cells. (A) NL-4/
5S6/7SvifS, a virus with the SIVmac L4/5, L6/7, and vif was inoculated 
into CEMss cells, and culture supernatants were periodically assayed 
for the levels of p24. (B) Virus in the culture supernatant on day 42 after 
infection (NL-4/5S6/7SvifSd42) was inoculated into fresh CEMss cells.
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amino acid position rescued the impaired growth capa-
bility of NL-4/5S6/7SvifS in human cells, we investigated
whether NL-4/5SG116E6/7SvifS could grow in human
cells expressing CM TRIM5α (Figure 4A). For TRIM5α
expression, we used SeV expressing CM TRIM5α or
human TRIM5α. SeV expressing CM-SPRY (-) was used
as a TRIM5α-negative control [31]. NL-SVR, a virus with
SIVmac vif renamed NL-vifS in the present study, did not
grow at all in CEMss cells expressing CM TRIM5α. In
contrast, NL-4/5SG116E6/7SvifS could grow in CEMss
cells expressing CM TRIM5α (Figure 4A), although the
viral titers were less than 10% of those in the absence of
TRIM5α. Similarly, the human cell-adapted virus NL-4/
5S6/7SvifSd42 could also grow in CEMss cells expressing
CM TRIM5α (data not shown). To clarify the impact of
the single G-to-E substitution in CA on virus growth in
the presence of CM TRIM5α, we next introduced a
G116E substitution in NL-vifS to generate NL-G116EvifS.
We first anticipated that this virus would fail to replicate
in CEMss cells expressing CM TRIM5α. Contrary to our
expectations, however, this virus grew in the presence of
CM TRIM5α to levels similar to those of NL-4/
5SG116E6/7SvifS. This result indicates that the single
amino acid residue in CA could affect the viral sensitivity
to CM TRIM5α mediated restriction. To exclude any pos-
sible effect of SIVmac vif in NL-G116EvifS on TRIM5α-
mediated restriction, we constructed NL-G116E, a virus
with a single amino acid substitution at the 116th posi-
tion of the CA only (Figure 4B). This virus could also rep-
licate in CEMss cells expressing CM TRIM5α, confirming
the importance of the 116th amino acid residue of the CA
in TRIM5α-mediated restriction.
With respect to viral sensitivity to human TRIM5α, the
growth of both NL-G116EvifS and NL-4/5SG116E6/
7SvifS was slightly impaired compared with that of NL-
vifS in CEMss cells over-expressing human TRIM5α. The
growth of the NL4-3 virus was not affected by human
TRIM5α, while that of NL-G116E was slightly suppressed
by human TRIM5α. These results suggest that the viruses
with G116E substitution were more sensitive to human
TRIM5α although the G116E substitution occurred dur-
ing long-term cultivation of human cells infected with
NL-4/5S6/7SvifS. This excludes a possibility that the
improved replicative capability of human cell-adapted
virus is the result of escape from human TRIM5α-medi-
ated restriction.
A G116E substitution affects viral sensitivity to CM TRIM5α-
mediated restriction in a single-round infection assay
The assay described in Figures 3 and 4 investigated the
effects of CM TRIM5α on the multi-step growth of the
viruses. T o evaluate the effects of CM TRIM5α on the
early steps of viral infection, we performed a single-round
infection assay. The fragment of NL-G116E, NL-4/5S6/
7SvifS, or NL-4/5SG116E6/7SvifS corresponding to the
MA and CA was transferred to an env-deleted HIV-1
genomic clone, which express GFP after infection. VSV-G
pseudotyped wild type and mutant HIV-1 GFP viruses
w e r e  i n o c u l a t e d  i n t o  C E M s s  c e l l s  e x p r e s s i n g  T R I M 5 α
and GFP positive cells were counted 2 days after infection
(Figure 5A). Because the replicative capability of NL-4/
5S6/7SvifS in human cells was lower than that of the wild
type virus as described above, it was highly likely that the
infectivity of 4/5S6/7S-GFP would also be lower than
those of WT-GFP and G116E-GFP. Therefore, we used
higher input doses of 4/5S6/7S-GFP and 4/5SG116E6/7S-
GFP than those of WT-GFP and G116E-GFP. Ratios of
the GFP-positive percentage of cells expressing CM
TRIM5α to those of cells expressing non-functional CM-
SPRY(-)-TRIM5α are shown as percent of infection in
Figure 3 Replication properties of HIV-1 derivatives. Equal 
amounts of NL-4/5SvifS (white diamonds: virus with SIVmac L4/5 and 
vif), NL-4/5S6/7SvifS (white squares: virus with SIVmac L4/5, L6/7, and 
vif), or NL-4/5SG116E6/7SvifS (black squares: virus with the additional 
replacement of the 116th amino acid Gly with Glu in NL-4/5S6/7SvifS) 
were inoculated into human CEMss or MT4 cells, and culture superna-
tants were collected periodically. The levels of p24 antigen were mea-
sured by ELISA. A representative of three independent experiments is 
shown.
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Figure 5B. The percent of infection was relatively con-
stant among the different input doses. Consistent with
the results that NL-G116E could replicate in human cells
expressing CM TRIM5α (Figure 4B), the GFP-expressing
virus with the G116E substitution was more resistant to
CM TRIM5α-mediated restriction than the wild type
virus, while both viruses were completely restricted by Rh
TRIM5α (Figure 5A, Figure 5B left). Similar results were
o b t a i n e d  w h e n  w e  u s e d  C f 2 T h  c a n i n e  c e l l s  l a c k i n g
endogenous TRIM5α expression, although the number of
GFP-positive cells was less than that of CEMss cells (data
not shown). These results in the single-round infection
assay clearly confirmed our results in the live virus repli-
cation experiments showing that the G116E substitution
conferred resistance against CM-TRIM5α-mediated
restriction. While both the GFP-expressing viruses with
the 4/5S6/7S (4/5S6/7S-GFP and 4/5SG116E6/7S-GFP)
were resistant to CM TRIM5α, an additional effect of the
G116E substitution was not observed (Figure 5B, left). To
examine the effect of G116E substitution in cells with
more physiological levels of TRIM5α expression, we
established TK-ts13 hamster cells stably expressing CM
or human TRIM5α and inoculated lentivector expressing
GFP under the cytomegalovirus promoter into these
cells. As shown in Figure 5C and 5D, the GFP expression
from the lentivector with the wild type CA was sup-
pressed in TK-ts13 cells expressing CM TRIM5α,
although the levels of suppression were less than those in
Figure 5B due to lower levels of CM TRIM5α expression.
As expected, the lentivector with the G116E substitution
showed reduced suppression by CM TRIM5α compared
with the wild type CA (Figures 5C and 5D).
Figure 4 Viral growth in the presence of TRIM5α. CEMss cells were infected with recombinant Sendai virus (SeV) expressing CM (black diamonds), 
human (gray circles), or CM-SPRY (-) (white diamonds) TRIM5α. Nine hours after infection, cells were superinfected with the indicated HIV-1 derivatives. 
Culture supernatants were separately assayed for levels of p24. Error bars show actual fluctuations between levels of p24 in duplicate samples. A rep-
resentative of three independent experiments is shown.
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On the contrary, the GFP-expressing virus with G116E
was more sensitive to humanTRIM5α expressed from the
SeV in CEMss cells than the wild type virus (Figure 5B,
right). These results again confirmed the results in the
live virus replication experiments shown in Figure 4. In
the case of TK-ts13, cells stably expressing human
TRIM5α in which TRIM5α expression is in more physio-
logical levels; however, the difference in sensitivity to
human TRIM5α between the wild type and G116E len-
tivector was not observed (Figure 5C and 5D). Further-
more, when we used TRIM5α knockout Jurkat cells, we
also failed to detect the difference in sensitivity to human
TRIM5α between the wild type and G116E virus (data
not shown). These results indicated that the effect of
G116E substitution is virtually negligible at physiological
levels of endogenous human TRIM5α, although this sub-
Figure 5 Viral sensitivity to TRIM5α-mediated restriction in a single-round infection assay. CEMss cells were infected with SeVs expressing CM 
(black diamonds), human (Hu: gray circles), rhesus monkey (Rh: black triangles), or CM-SRPY(-) (white circles) TRIM5α. The cells were then superinfected 
with serially diluted HIV-1-GFP with the indicated CA. (B) The percentage of the GFP-positive cells in the presence of TRIM5α was divided by the per-
centage of GFP-positive cells in the presence of CM SPRY (-) TRIM5α to define percent infection. The differences in percent infection between WT-GFP 
and G116E-GFP, or 4/5S6/7S-GFP and 4/5SG116E6/7S-GFP were statistically evaluated by unpaired t test (*: P < 0.05, **; P < 0.01). The representative 
results of three independent experiments with similar results are shown. (C) TK-ts13 cells stably expressing CM (black diamonds), human (Hu: gray 
circles), or CM-SRPY(-) (white circles) TRIM5α were infected with serially diluted lentivector expressing GFP under the control of cytomegalovirus pro-
moter with the indicated CA. (D) The percentage of the GFP-positive cells in the presence of TRIM5α was divided by the percentage of GFP-positive 
cells in the presence of CM SPRY (-) TRIM5α to define percent infection. The differences in percent infection between the wild type and G116E were 
statistically evaluated by unpaired t test (**; P < 0.01). The representative results of three independent experiments with similar results are shown.
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stitution increases the susceptibility of HIV-1 to human
TRIM5α.
A G-to-E substitution at the 116th position did not affect 
the association between CA and CypA or Gag processing
To clarify whether the 116th amino acid substitution
affects the association of CypA with CA, the CypA con-
tent in the wild type and mutant virions was evaluated by
Western blot analysis. As shown in Figure 6, CypA was
detected in virions with HIV-1 L4/5 (lanes 1 to 4, upper
panel), but not in those with SIVmac L4/5 (lanes 5 to 7)
indicating that the G-to-E substitution at the 116th
amino acid position had no effect on CypA binding of
HIV-1 CA. When we used anti-p24 antibody (Figure 6,
lower panel), p55 Gag precursors and mature p24 CA
were detected. The HIV-1 Gag precursor proteins with
SIVmac L4/5 and L6/7 were processed nearly normally in
the virion, although there were slight differences in the
ratios of p24 to p55 among HIV-1 derivatives (Figure 6,
bottom). In particular, the virus with SIVmac L4/5 and
L6/7 tended to contain increased amount of p55 Gag pre-
cursors (lane 6, bottom); however, addition of G116E sub-
stitution did not facilitate the cleavage of Gag (lane 7).
Structural model of the capsid protein
To obtain further insight into the effects of the G-to-E
single amino acid substitution at the 116th position of the
CA on its three-dimensional (3-D) structure, the 3-D
model of the N-terminus of the CA was constructed by
homology-modeling on the basis of the published crystal
structure of the N-terminus of the CA of NL4-3 (PDB
number 1GWP) [29] (Figure 7). Position 116 is located in
the 6th helix near the L4/5 and L6/7 and is apparently
exposed to the surface of the protein (Figure 7 upper pan-
els). The substitution of G to E might be important
because in contrast to G, which lacks a side chain, E has a
long side chain with a negative charge (Figure 7 lower
panels). The mutation can therefore have two possible
effects. First, if the residue is located in the interaction
site, it can change the local complementarity between CA
and TRIM5α. Second, even if the residue is not directly in
the binding site, the change in the side chain and polarity
can influence the configuration of nearby loops and,
thereby, influence a binding site that is located some-
where else on the protein. Notably, the loops being flexi-
ble parts of the protein are slightly repositioned in the
modeled structure with G116E substitution (Figure 7A
and 7B).
Figure 6 Western blot analysis of the CA and cyclophilin A (CypA) 
in particles of HIV-1 derivatives. Viral particles of the indicated HIV-1 
derivatives were purified by ultracentrifugation through a 20% sucrose 
cushion. CypA, p24, and p55 proteins were visualized by Western blot-
ting (WB) using anti-CypA and anti-p24 antibody, respectively. "H" and 
"S" denote the amino acid sequences derived from HIV-1 and 
SIVmac239, respectively. The ratio of the amount of p24 to that of p55 
of each virus is shown at the bottom. A representative of three inde-
pendent experiments is shown.
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Discussion
By long-term cultivation of human CEMss cells infected
with NL-ScaVR6/7S (NL-4/5S6/7SvifS), a simian tropic
HIV-1 that could grow efficiently in CM cells but ineffi-
c i e n t l y  i n  h u m a n  c e l l s ,  w e  s u c c e e d e d  i n  r e s c u i n g  t h e
impaired replicative capability of the virus in human cells.
Sequence analysis of the MA-CA region of the adapted
virus revealed that the there was a G-to-E single amino
acid substitution at the 116th position of the CA. Intro-
duction of this substitution into the molecular DNA
clone of NL-4/5S6/7SvifS indeed improved the virus' rep-
licative capability in human cells. We thus concluded that
the recovered replicative capability in human cells was
mainly the result of acquisition of the single amino acid
substitution at the 116th position of the CA, although
small effects of mutations in regions other than the MA-
CA cannot be fully excluded at present.
Although the 116th position of the CA is highly vari-
able among natural HIV-1 strains from subtypes A to K,
no virus with E at the 116th position was found in the Los
Alamos HIV sequence database 2009 http://
www.hiv.lanl.gov/. On the other hand, most HIV-2 and
SIVmac strains have glutamine, which has a long side
chain similar to E, at this position, and some strains have
E. It is possible that the combination of the amino acid
residue at the 116th position and L6/7 is important for
viral growth. Consistent with this hypothesis, NL-4/
5SG116EvifS, a virus with an HIV-1 derived L6/7 and the
G116E substitution, showed impaired growth in MT4
cells (data not shown).
The precise reasons for the impaired replicative capa-
bility of NL-4/5S6/7SvifS and effect of G116E in human
cells remain to be elucidated. Analysis of a series of CA
mutants shown in Figures 4 and 5 clearly excluded the
possibility that the impaired replicative capability of NL-
4/5S6/7SvifS in human cells resulted from an increased
sensitivity to human TRIM5α because a virus with the
SIVmac L4/5 and L6/7 (4/5S6/7S) showed similar infec-
tivity to the wild-type virus in the presence of human
TRIM5α, and a virus with the SIVmac L4/5, L6/7, and
G116E substitution (4/5SG116E6/7S) became more sen-
sitive to human TRIM5α (Figure 5B). On the other hand,
the virus with the SIVmac L4/5 and L6/7 showed slightly
impaired cleavage of p55 Gag precursors, although p24
mature CA proteins were clearly detected (Figure 6).
However, the addition of G116E substitution did not
facilitate the cleavage of Gag, and a small defect in Gag
processing could only partially explain the attenuated
growth of NL-4/5S6/7SvifS. Another possibility is that
NL-4/5S6/7SvifS was restricted by a certain intrinsic
restriction factor that was previously suggested to be
present in human cells [13,14], and that the adapted virus
could escape from this restriction by G116E substitution,
since the G116E was acquired through the adaptation in
human cells. It is thus necessary to conduct further analy-
sis to substantiate this unidentified restriction factor.
Although the G116E substitution occurred during
long-term cultivation of human cells infected with NL-4/
5S6/7SvifS, the viruses with G116E unexpectedly became
resistant to CM TRIM5α-mediated restriction (Figures 4
and 5). Replacing the HIV-1 L6/7 (HNPPIP) of the CA
with that of SIVmac239 (RQQNPIP) resulted in elonga-
tion of the loop by one amino acid, and it is reasonable to
assume that the G116E substitution occurred to compen-
sate the structural warp caused by the extended L6/7.
This compensatory substitution occurred at the central
position of the surface composed of L4/5 and L6/7, a
structure considered to be important for TRIM5α bind-
ing [24]. The amino acid substitution of G with E at the
116th position caused an important change in the struc-
ture of the surface composed of L4/5 and L6/7 because G,
which has no side chain, was replaced by E, which has a
long, negatively charged side chain as shown in Figure 7.
This change in the conformational structure of L4/5 and
L6/7 might affect the interaction between the CA and
TRIM5α. Alternatively, this single amino acid substitu-
tion might influence the configuration of surrounding
loops by the changes in the side chain and polarity with-
out directly involving the binding site of TRIM5α.
Conclusion
We succeeded in rescuing the impaired replicative capa-
bility of simian tropic HIV-1 NL-4/5S6/7SvifS and unex-
pectedly identified a single amino acid substitution in the
CA that affects viral sensitivity to CM TRIM5α-mediated
restriction. This finding will increase our understanding
of the detailed molecular interactions between the CA
and TRIM5α.
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